Wednesday, February 3, 2021

Obesity | HPV | Jaw Problems, Cancer Information Highlights, 02/03/2021

National Cancer Institute

Having trouble viewing this email? View it as a Web page.

Bookmark and Share

Cancer Information Highlights
From the National Cancer Institute
Updating you about cancer causes, prevention, screening, treatment, coping, and more
 
maximus posuere.
New from NCI
Obesity May Help Tumors Survive and Grow
Illustration shows green T cells interacting with tumor cells   A study in mice has shown that obesity changed the relationship between cancer cells and nearby immune cells in ways that helped tumors survive and grow. But changing how cancer cells make and use energy helped immune cells once again find and get into tumors.
HPV and Cancer
diagram of HPV in the middle surrounded by the cancers it can cause   Human papillomavirus (HPV) is a virus that can cause many types of cancer. Learn more about HPV, how it causes cancer, how it spreads, screening tests that can find cell changes caused by HPV, and the vaccine that can prevent cancer from forming.
Study Explores Jaw Problem Linked to Zoledronic Acid

Read about a recent study that measured the risk of osteonecrosis of the jaw for people who take zoledronic acid to manage problems from cancer that has spread to the bone. The study also looked at risk factors that may lead to this side effect.
New Approval Expected to Change Treatment for Advanced Prostate Cancer

The Food and Drug Administration's (FDA) recent approval of relugolix (Orgovyx) is expected to affect the treatment of men with advanced prostate cancer. A large clinical trial showed that relugolix was more effective at reducing testosterone levels than another common treatment.

PDQ Updates
Last Days of Life

Our PDQ summary Last Days of Life has had a major revision. It includes updated information about care at the end of life, including common symptoms and questions about treatment that may come up, to help people with cancer and their families understand what to expect during this time.
FDA Approvals
Nivolumab and Cabozantinib-S-Malate for Renal Cell Carcinoma

We've updated our drug summaries on nivolumab (Opdivo) and cabozantinib-s-malate (Cabometyx) with a recent FDA approval. These drugs are now approved to be used together as first-line therapy for people with advanced renal cell carcinoma (a type of kidney cancer).
 
Also of Interest
Cancer Currents Blog Posts about Treatment

See all the Cancer Currents blog posts about treatment in one place. The collection includes articles on new treatments, side effects, and important treatment-related research trends.
Cancer Prevention

Our expert-reviewed page on ways to prevent cancer covers risk factors to avoid, how to live a healthy lifestyle, screening tests you should have, and the role of certain medicines or surgery.
Contact Us for Help

Information specialists at NCI's Cancer Information Service (CIS), NCI's contact center, are available to help answer your cancer-related questions in English and Spanish. Reach us by phone, chat, or email.

 

This email was sent to myhcistech.healthnews360@blogger.com using GovDelivery Communications Cloud on behalf of: National Cancer Institute · BG 9609 MSC 9760 · 9609 Medical Center Drive · Bethesda, MD 20892 GovDelivery logo

No comments:

Post a Comment